Faillie Jean-Luc
Regional Pharmacovigilance Centre, Department of Medical Pharmacology and Toxicology, CHU de Montpellier, 34295 Montpellier, France; Laboratory of Biostatistics, Epidemiology and Public Health, EA2415, Faculty of Medicine, University of Montpellier, University Institute of Clinical Research, 34295 Montpellier, France.
Therapie. 2019 Apr;74(2):225-232. doi: 10.1016/j.therap.2019.01.006. Epub 2019 Jan 31.
Case-non-case studies are among the methods used to assess drug safety by analyzing the disproportionality of adverse drug reaction reports in pharmacovigilance databases. First used in the 1980s, the last few decades have seen a significant increase in the use of this study design. The principle of case-non-case studies is to compare the drug exposure of cases of an adverse reaction of interest with that of cases with other reported reactions and called "non-cases". Their results are presented in the form of reporting odds ratio (ROR), the interpretation of which makes it possible to highlight pharmacovigilance signals. This article describes the principle of case-non-case studies, the calculation method of the ROR and its confidence interval, the different analytical modalities and how to interpret its results with regard to the advantages and limitations of this type of study.
病例-非病例研究是通过分析药物警戒数据库中药物不良反应报告的不成比例性来评估药物安全性的方法之一。该研究设计于20世纪80年代首次使用,在过去几十年中其使用量显著增加。病例-非病例研究的原则是将感兴趣的不良反应病例的药物暴露情况与其他报告反应的病例(称为“非病例”)的药物暴露情况进行比较。其结果以报告比值比(ROR)的形式呈现,对其进行解释有助于突出药物警戒信号。本文描述了病例-非病例研究的原则、ROR及其置信区间的计算方法、不同的分析方式以及如何根据这类研究的优缺点来解释其结果。